GOSERELIN 3.6mg (Zoladex®)
Clinical Indication
Breast cancer
Comments
Zoladex 3.6mg implant is the only licensed product for breast cancer
Local guidance
To be included in the primary care enhanced service for administration
Date of classification
May 2016
Yellow
Specialist recommendation: Medicines initiated (and stabilised where appropriate) or recommended by a specialist service for prescribing in primary care. Requests should be clearly communicated either through written communication including using approved paperwork if available or verbal means as appropriate .